Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Regorafenib in Advanced Pancreatic Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02080260
Recruitment Status : Completed
First Posted : March 6, 2014
Results First Posted : July 19, 2019
Last Update Posted : July 19, 2019
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Stuart Salmon, MD, Atrium Health

Brief Summary:
This study tests regorafenib as a single agent in the treatment of metastatic pancreatic cancer patients who have progressed after prior chemotherapy with gemcitabine. The prognosis for these patients is particularly grim, no other standard treatment options exist, and novel approaches are desperately needed.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: regorafenib Phase 2

Detailed Description:
This is a single arm, single stage Phase II study designed to evaluate progression free survival (PFS) in patients with metastatic pancreatic cancer who have failed at least one prior line of therapy and treatment with gemcitabine. This study is open at the Levine Cancer Institute (LCI). A total of 32 patients will be enrolled over a two years. Following informed consent and eligibility check, all patients will start oral regorafenib therapy (120 mg daily for 3 weeks on / 1 week off; 28 day cycle) with a built-in dose escalation to 160mg after the first cycle as tolerated, and will continue therapy until progression or patient withdrawal. Patients will undergo radiological staging after the first two cycles of regorafenib therapy. Patients with progressive disease will be removed from the study. Patients who have at least stable disease will continue regorafenib therapy, at the Investigator's discretion, and will be radiologically restaged bimonthly.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Actual Study Start Date : June 6, 2014
Actual Primary Completion Date : June 28, 2017
Actual Study Completion Date : June 28, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Regorafenib

Arm Intervention/treatment
Experimental: Single Arm
Oral Regorafenib
Drug: regorafenib
Single agent drug therapy with regorafenib
Other Name: Stivarga




Primary Outcome Measures :
  1. Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects [ Time Frame: 16 weeks after enrollment ]
    16-week progression free survival was determined for each subject as a binary variable indicating whether or not the subject is alive and progression free at 16 weeks after treatment start, with progression defined radiographically using RECIST v1.1 or clinically based upon investigator assessment.


Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: From date of treatment start to date of progression or death, or censored as described above; assessed for approximately 3 years. ]
    PFS is defined as duration of time from enrollment to the study to time of progression or death. Disease progression (PD) can be objectively determined as per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors, where PD is defined as a 20% increase in the sum of the longest diseased of target lesions, or a measurable increase in non-target lesion, or the appearance of new lesions) or progression can be subjective as determined by the investigator. Evidence for subjective progressions must be documented in medical records. For surviving subjects who do not have documented PD, PFS will be censored at last radiologic assessment. For subjects who receive subsequent anti-cancer therapy prior to documented PD, PFS will be censored at last radiologic assessment prior to commencement of subsequent therapy. Subjects who experience a PFS event following an interval equal to two or more scheduled CT assessments will be censored at date of last assessment prior to first missed assessment.

  2. Overall Survival [ Time Frame: From date of treatment start to date of death, or censored as described above; assessed for approximately 3 years. ]
    Overall survival is defined as the duration from enrollment date to the date of death from any cause. Subjects who are alive or lost to follow-up at the time of the analysis will be censored at the last known date they were alive.

  3. Overall Response [ Time Frame: From enrollment to best response while on regorafenib; Subjects remained on treatment until disease progression or death or discontinuation from study or at least 28 days after last dose (subjects were on treatment for an average of 6 weeks) ]
    Overall response will be determined as the best treatment response for each patient as a binary variable indicating whether or not the patient achieved a Complete Response (CR) or Partial Response (PR) as determined by RECIST v1.1 criteria. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1):Complete Response (CR) is the disappearance of all lesions (target and non target); Partial Response (PR) is at least 30% decrease in the sum of the diameters of target lesions from baseline and no new lesions or unequivocal progression in non target lesions from baseline; Stable Disease (SD) is neither sufficient shrinkage in target lesions to qualify for PR (less than 30% decrease) nor sufficient increase in target lesions (versus smallest sum of diameters) to qualify for PD (less than 20% increase), with no new lesions or unequivocal progression in non target lesions from baseline. For the purposes of response determination, confirmatory scan for CR and PR is not required.

  4. Disease Control [ Time Frame: From enrollment to best response while on regorafenib; Subjects remained on treatment until disease progression or death or discontinuation from study or at least 28 days after last dose (subjects were on treatment for an average of 6 weeks) ]
    Disease control will be determined for each patient as a binary variable indicating whether or not the patient achieved a best overall best response of CR, PR, or stable disease as determined by RECIST v1.1 criteria. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v 1.1): Complete Response (CR) is the disappearance of all lesions (target and non target); Partial Response (PR) is at least 30% decrease in the sum of the diameters of target lesions from baseline and no new lesions or unequivocal progression in non target lesions from baseline; Stable Disease (SD) is neither sufficient shrinkage in target lesions to qualify for PR (less than 30% decrease) nor sufficient increase in target lesions (versus smallest sum of diameters) to qualify for PD (less than 20% increase), with no new lesions or unequivocal progression in non target lesions from baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adenocarcinoma of the exocrine pancreas with metastatic disease.
  • The site of the primary tumor confirmed to have been within the pancreas.
  • Progression on at least one prior line of chemotherapy for locally-advanced or metastatic pancreatic cancer.
  • Progression while on treatment with a gemcitabine regimen for advanced pancreatic cancer, or within 12 months of treatment with gemcitabine as part of adjuvant therapy.
  • Measurable disease on axial imaging.
  • Age greater than or equal to 18 years.
  • Life expectancy of at least 8 weeks.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2. Enrollment of patients with PS = 2 will be capped at 7 patients.
  • Subjects must be able to understand and be willing to sign the written informed consent form.
  • Acute toxic effects except alopecia of any prior treatment must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Grade 1 or less.
  • Adequate bone marrow, renal, and liver function.
  • Warfarin or heparin will be allowed provided that there is no prior evidence of underlying coagulation abnormality.
  • Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.
  • Patients (men and women) of childbearing potential must agree to use adequate contraception
  • Patient must be able to swallow and retain oral medication.

Exclusion Criteria:

  • Previous assignment to treatment during this study.
  • Uncontrolled hypertension.
  • Active clinically significant cardiac disease.
  • Cerebrovascular arterial event within 6 months.
  • Evidence or history of bleeding diathesis or coagulopathy.
  • Any bleeding event greater than or equal to NCI CTCAE Grade 3 within 4 weeks.
  • New venous thrombotic or embolic events, such as deep vein thrombosis or pulmonary embolism within 3 months.
  • Previously untreated or concurrent cancer that is distinct in primary site or histology except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor. Patients surviving a cancer that was curatively treated and without evidence of disease for more than 3 years are allowed.
  • Patients with pheochromocytoma.
  • Known history of HIV infection or current chronic or active hepatitis B or C, requiring antiviral medication.
  • Ongoing infection greater than or equal to Grade 2 NCI-CTCAE v4.0.
  • Symptomatic metastatic brain or meningeal tumors.
  • Presence of a non-healing wound, non-healing ulcer, or bone fracture.
  • Renal failure requiring dialysis.
  • Dehydration Grade greater than or equal to 1 NCI-CTCAE v4.0.
  • Patients with seizure disorder requiring medication.
  • Persistent proteinuria greater than or equal to Grade 3 NCI-CTCAE v4.0.
  • Symptomatic interstitial lung disease.
  • Pleural effusion or ascites that cause respiratory compromise.
  • History of organ allograft except corneal transplant.
  • Known or suspected allergy or hypersensitivity to the study drugs.
  • Any severe, uncontrolled malabsorption condition.
  • Women who are pregnant or breast-feeding.
  • Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study.
  • Concurrent anti-cancer therapy other than study treatment (regorafenib).
  • Prior use of regorafenib.
  • Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days.
  • Prior radiation therapy or hepatic arterial therapy is permitted if more than 4 weeks have passed since completion and measurable disease outside of the treated area is present, or if progression since treatment has occurred.
  • Use of St. John's Wort.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02080260


Locations
Layout table for location information
United States, North Carolina
Levine Cancer Institute-Albemarle
Albemarle, North Carolina, United States, 28001
Levine Cancer Institute-South Tryon
Charlotte, North Carolina, United States, 28203
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
Levine Cancer Institute - Pineville
Charlotte, North Carolina, United States, 28210
Levine Cancer Institute - Southpark
Charlotte, North Carolina, United States, 28211
Levine Cancer Institute - Mallard Creek
Charlotte, North Carolina, United States, 28262
Levine Cancer Institute - University
Charlotte, North Carolina, United States, 28262
Levine Cancer Institute - Ballantyne
Charlotte, North Carolina, United States, 28277
Levine Cancer Institute - Concord
Concord, North Carolina, United States, 28025
Levine Cancer Institute-Monroe
Monroe, North Carolina, United States, 28112
Levine Cancer Institute - Cleveland
Shelby, North Carolina, United States, 28150
United States, South Carolina
Low Country Hematology Oncology
Charleston, South Carolina, United States, 29406
Sponsors and Collaborators
Stuart Salmon, MD
Bayer
Investigators
Layout table for investigator information
Principal Investigator: John S Salmon, MD Levine Cancer Institute
Principal Investigator: Edward Kim, MD Levine Cancer Institute
  Study Documents (Full-Text)

Documents provided by Stuart Salmon, MD, Atrium Health:

Layout table for additonal information
Responsible Party: Stuart Salmon, MD, Sponsor-Investigator, Atrium Health
ClinicalTrials.gov Identifier: NCT02080260     History of Changes
Other Study ID Numbers: LCI-GI-PAN-REG-001
First Posted: March 6, 2014    Key Record Dates
Results First Posted: July 19, 2019
Last Update Posted: July 19, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases